Research programme: oral psoriasis therapeutics - 4SC Discovery
Latest Information Update: 16 Jul 2016
At a glance
- Originator 4SC Discovery; LEO Pharma
- Mechanism of Action Cytokine modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis